Eintrag weiter verarbeiten
Toxic Effects of Metallopharmaceuticals
Gespeichert in:
| Zeitschriftentitel: | Serbian Journal of Experimental and Clinical Research |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Serbian Journal of Experimental and Clinical Research, 18, 2017, 3, S. 191-194 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Walter de Gruyter GmbH
|
| Schlagwörter: |
| author_facet |
Novokmet, Slobodan Stojic, Isidora Radonjic, Katarina Savic, Maja Jeremic, Jovana Novokmet, Slobodan Stojic, Isidora Radonjic, Katarina Savic, Maja Jeremic, Jovana |
|---|---|
| author |
Novokmet, Slobodan Stojic, Isidora Radonjic, Katarina Savic, Maja Jeremic, Jovana |
| spellingShingle |
Novokmet, Slobodan Stojic, Isidora Radonjic, Katarina Savic, Maja Jeremic, Jovana Serbian Journal of Experimental and Clinical Research Toxic Effects of Metallopharmaceuticals General Medicine |
| author_sort |
novokmet, slobodan |
| spelling |
Novokmet, Slobodan Stojic, Isidora Radonjic, Katarina Savic, Maja Jeremic, Jovana 2335-075X 1820-8665 Walter de Gruyter GmbH General Medicine http://dx.doi.org/10.1515/sjecr-2016-0082 <jats:title>Abstract</jats:title> <jats:p> Discovery of the metallopharmaceutical cisplatin and its use in antitumour therapy has initiated the rational design and screening of metal-based anticancer agents as potential chemotherapeutics. In addition to the achievements of cisplatin and its therapeutic analogues, there are significant drawbacks to its use: resistance and toxicity. Over the past four decades, numerous transition metal complexes have been synthesized and investigated in vitro and in vivo. The most studied metals among these complexes are platinum and ruthenium. The key features of these investigations is to find novel metal complexes that could potentially exert less toxicity and equal or higher antitumour potency and to overcome other pharmacological deficiencies. Ru complexes have a different mode of action than cisplatin does, some of which are under clinical trials for treating metastatic or cisplatin-resistant tumours. This review consists of the current knowledge, published and unpublished, related to the toxicity of metallopharmaceuticals, and special attention is given to platinum [Pt(II) and Pt(IV)] and ruthenium [Ru(II) and Ru(III)] complexes.</jats:p> Toxic Effects of Metallopharmaceuticals Serbian Journal of Experimental and Clinical Research |
| doi_str_mv |
10.1515/sjecr-2016-0082 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9zamVjci0yMDE2LTAwODI |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9zamVjci0yMDE2LTAwODI |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Walter de Gruyter GmbH, 2017 |
| imprint_str_mv |
Walter de Gruyter GmbH, 2017 |
| issn |
1820-8665 2335-075X |
| issn_str_mv |
1820-8665 2335-075X |
| language |
English |
| mega_collection |
Walter de Gruyter GmbH (CrossRef) |
| match_str |
novokmet2017toxiceffectsofmetallopharmaceuticals |
| publishDateSort |
2017 |
| publisher |
Walter de Gruyter GmbH |
| recordtype |
ai |
| record_format |
ai |
| series |
Serbian Journal of Experimental and Clinical Research |
| source_id |
49 |
| title |
Toxic Effects of Metallopharmaceuticals |
| title_unstemmed |
Toxic Effects of Metallopharmaceuticals |
| title_full |
Toxic Effects of Metallopharmaceuticals |
| title_fullStr |
Toxic Effects of Metallopharmaceuticals |
| title_full_unstemmed |
Toxic Effects of Metallopharmaceuticals |
| title_short |
Toxic Effects of Metallopharmaceuticals |
| title_sort |
toxic effects of metallopharmaceuticals |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1515/sjecr-2016-0082 |
| publishDate |
2017 |
| physical |
191-194 |
| description |
<jats:title>Abstract</jats:title>
<jats:p> Discovery of the metallopharmaceutical cisplatin and its use in antitumour therapy has initiated the rational design and screening of metal-based anticancer agents as potential chemotherapeutics. In addition to the achievements of cisplatin and its therapeutic analogues, there are significant drawbacks to its use: resistance and toxicity. Over the past four decades, numerous transition metal complexes have been synthesized and investigated in vitro and in vivo. The most studied metals among these complexes are platinum and ruthenium. The key features of these investigations is to find novel metal complexes that could potentially exert less toxicity and equal or higher antitumour potency and to overcome other pharmacological deficiencies. Ru complexes have a different mode of action than cisplatin does, some of which are under clinical trials for treating metastatic or cisplatin-resistant tumours. This review consists of the current knowledge, published and unpublished, related to the toxicity of metallopharmaceuticals, and special attention is given to platinum [Pt(II) and Pt(IV)] and ruthenium [Ru(II) and Ru(III)] complexes.</jats:p> |
| container_issue |
3 |
| container_start_page |
191 |
| container_title |
Serbian Journal of Experimental and Clinical Research |
| container_volume |
18 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792335831173693447 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:50:48.307Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Toxic+Effects+of+Metallopharmaceuticals&rft.date=2017-10-26&genre=article&issn=1820-8665&volume=18&issue=3&spage=191&epage=194&pages=191-194&jtitle=Serbian+Journal+of+Experimental+and+Clinical+Research&atitle=Toxic+Effects+of+Metallopharmaceuticals&aulast=Jeremic&aufirst=Jovana&rft_id=info%3Adoi%2F10.1515%2Fsjecr-2016-0082&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792335831173693447 |
| author | Novokmet, Slobodan, Stojic, Isidora, Radonjic, Katarina, Savic, Maja, Jeremic, Jovana |
| author_facet | Novokmet, Slobodan, Stojic, Isidora, Radonjic, Katarina, Savic, Maja, Jeremic, Jovana, Novokmet, Slobodan, Stojic, Isidora, Radonjic, Katarina, Savic, Maja, Jeremic, Jovana |
| author_sort | novokmet, slobodan |
| container_issue | 3 |
| container_start_page | 191 |
| container_title | Serbian Journal of Experimental and Clinical Research |
| container_volume | 18 |
| description | <jats:title>Abstract</jats:title> <jats:p> Discovery of the metallopharmaceutical cisplatin and its use in antitumour therapy has initiated the rational design and screening of metal-based anticancer agents as potential chemotherapeutics. In addition to the achievements of cisplatin and its therapeutic analogues, there are significant drawbacks to its use: resistance and toxicity. Over the past four decades, numerous transition metal complexes have been synthesized and investigated in vitro and in vivo. The most studied metals among these complexes are platinum and ruthenium. The key features of these investigations is to find novel metal complexes that could potentially exert less toxicity and equal or higher antitumour potency and to overcome other pharmacological deficiencies. Ru complexes have a different mode of action than cisplatin does, some of which are under clinical trials for treating metastatic or cisplatin-resistant tumours. This review consists of the current knowledge, published and unpublished, related to the toxicity of metallopharmaceuticals, and special attention is given to platinum [Pt(II) and Pt(IV)] and ruthenium [Ru(II) and Ru(III)] complexes.</jats:p> |
| doi_str_mv | 10.1515/sjecr-2016-0082 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9zamVjci0yMDE2LTAwODI |
| imprint | Walter de Gruyter GmbH, 2017 |
| imprint_str_mv | Walter de Gruyter GmbH, 2017 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275 |
| issn | 1820-8665, 2335-075X |
| issn_str_mv | 1820-8665, 2335-075X |
| language | English |
| last_indexed | 2024-03-01T14:50:48.307Z |
| match_str | novokmet2017toxiceffectsofmetallopharmaceuticals |
| mega_collection | Walter de Gruyter GmbH (CrossRef) |
| physical | 191-194 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Walter de Gruyter GmbH |
| record_format | ai |
| recordtype | ai |
| series | Serbian Journal of Experimental and Clinical Research |
| source_id | 49 |
| spelling | Novokmet, Slobodan Stojic, Isidora Radonjic, Katarina Savic, Maja Jeremic, Jovana 2335-075X 1820-8665 Walter de Gruyter GmbH General Medicine http://dx.doi.org/10.1515/sjecr-2016-0082 <jats:title>Abstract</jats:title> <jats:p> Discovery of the metallopharmaceutical cisplatin and its use in antitumour therapy has initiated the rational design and screening of metal-based anticancer agents as potential chemotherapeutics. In addition to the achievements of cisplatin and its therapeutic analogues, there are significant drawbacks to its use: resistance and toxicity. Over the past four decades, numerous transition metal complexes have been synthesized and investigated in vitro and in vivo. The most studied metals among these complexes are platinum and ruthenium. The key features of these investigations is to find novel metal complexes that could potentially exert less toxicity and equal or higher antitumour potency and to overcome other pharmacological deficiencies. Ru complexes have a different mode of action than cisplatin does, some of which are under clinical trials for treating metastatic or cisplatin-resistant tumours. This review consists of the current knowledge, published and unpublished, related to the toxicity of metallopharmaceuticals, and special attention is given to platinum [Pt(II) and Pt(IV)] and ruthenium [Ru(II) and Ru(III)] complexes.</jats:p> Toxic Effects of Metallopharmaceuticals Serbian Journal of Experimental and Clinical Research |
| spellingShingle | Novokmet, Slobodan, Stojic, Isidora, Radonjic, Katarina, Savic, Maja, Jeremic, Jovana, Serbian Journal of Experimental and Clinical Research, Toxic Effects of Metallopharmaceuticals, General Medicine |
| title | Toxic Effects of Metallopharmaceuticals |
| title_full | Toxic Effects of Metallopharmaceuticals |
| title_fullStr | Toxic Effects of Metallopharmaceuticals |
| title_full_unstemmed | Toxic Effects of Metallopharmaceuticals |
| title_short | Toxic Effects of Metallopharmaceuticals |
| title_sort | toxic effects of metallopharmaceuticals |
| title_unstemmed | Toxic Effects of Metallopharmaceuticals |
| topic | General Medicine |
| url | http://dx.doi.org/10.1515/sjecr-2016-0082 |